LEVEL BIOTECHNOLOGY INC. Level Biotechnology Inc. Stock
Equities
3118
TW0003118006
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.6 TWD | +0.60% |
|
-0.30% | +10.34% |
| Sales 2022 | 593M 18.43M 25.09M | Sales 2023 | 661M 20.53M 27.96M | Capitalization | 988M 30.71M 41.82M |
|---|---|---|---|---|---|
| Net income 2022 | 58M 1.8M 2.45M | Net income 2023 | 62M 1.93M 2.62M | EV / Sales 2022 | 0.75 x |
| Net cash position 2022 | 451M 14.01M 19.08M | Net cash position 2023 | 454M 14.11M 19.21M | EV / Sales 2023 | 0.81 x |
| P/E ratio 2022 |
15.4
x | P/E ratio 2023 |
15.8
x | Employees | 126 |
| Yield 2022 |
6.15% | Yield 2023 |
5.58% | Free-Float | 70.27% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.60% | ||
| 1 week | -0.30% | ||
| Current month | +2.60% | ||
| 1 month | +1.05% | ||
| 3 months | +11.81% | ||
| 6 months | +10.53% | ||
| Current year | +10.34% |
1 week
32.90
34.05
1 month
32.7034.20
Current year
29.6034.50
1 year
29.2034.50
3 years
24.6034.75
5 years
19.9041.80
10 years
19.9046.15
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Lung Chiu
CEO | Chief Executive Officer | - | 97-07-31 |
Yi Hsien Li
DFI | Director of Finance/CFO | - | - |
Yi Chun Chiu
BRD | Director/Board Member | - | 96-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chin Yuan Lin
BRD | Director/Board Member | - | 19-06-16 |
Chun Lung Chiu
CEO | Chief Executive Officer | - | 97-07-31 |
Yi Chun Chiu
BRD | Director/Board Member | - | 96-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 33.6 | +0.60% | 115 699 |
| 24-05-27 | 33.4 | +0.91% | 108,655 |
| 24-05-24 | 33.1 | +0.30% | 55,667 |
| 24-05-23 | 33 | -2.37% | 148,541 |
| 24-05-22 | 33.8 | +0.30% | 78,864 |
End-of-day quote Taipei Exchange, May 27, 2024
More quotes
LEVEL BIOTECHNOLOGY INC. is a Taiwan-based company principally engaged in the agent distribution of biomedical related products. The Company's main products include cell culture series, immune protein series, gene nucleic acid and molecular biology series and instrument series. The Company also provides preclinical testing services, such as genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing and biocompatibility testing. The Company distributes its products in domestic market.
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +10.34% | 33.67M | |
| -7.64% | 181B | |
| -0.16% | 108B | |
| -7.14% | 66.12B | |
| +2.40% | 50.65B | |
| +5.16% | 43.11B | |
| +3.49% | 40.74B | |
| +19.70% | 31.6B | |
| +16.38% | 25.56B | |
| -7.12% | 24.16B |
- Stock Market
- Equities
- 3118 Stock
